Logo image of IPSC

CENTURY THERAPEUTICS INC (IPSC) Stock Fundamental Analysis

NASDAQ:IPSC - Nasdaq - US15673T1007 - Common Stock - Currency: USD

0.5556  +0 (+0.04%)

Fundamental Rating

2

Taking everything into account, IPSC scores 2 out of 10 in our fundamental rating. IPSC was compared to 566 industry peers in the Biotechnology industry. The financial health of IPSC is average, but there are quite some concerns on its profitability. IPSC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IPSC has reported negative net income.
In the past year IPSC has reported a negative cash flow from operations.
In the past 5 years IPSC always reported negative net income.
IPSC had negative operating cash flow in 4 of the past 5 years.
IPSC Yearly Net Income VS EBIT VS OCF VS FCFIPSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

IPSC's Return On Assets of -35.83% is fine compared to the rest of the industry. IPSC outperforms 60.25% of its industry peers.
IPSC has a Return On Equity (-78.44%) which is in line with its industry peers.
Industry RankSector Rank
ROA -35.83%
ROE -78.44%
ROIC N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
IPSC Yearly ROA, ROE, ROICIPSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IPSC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPSC Yearly Profit, Operating, Gross MarginsIPSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

IPSC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IPSC has more shares outstanding
IPSC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IPSC Yearly Shares OutstandingIPSC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPSC Yearly Total Debt VS Total AssetsIPSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -3.96, we must say that IPSC is in the distress zone and has some risk of bankruptcy.
IPSC has a Altman-Z score (-3.96) which is comparable to the rest of the industry.
There is no outstanding debt for IPSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.92%
IPSC Yearly LT Debt VS Equity VS FCFIPSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.50 indicates that IPSC should not have too much problems paying its short term obligations.
IPSC has a Current ratio of 1.50. This is amonst the worse of the industry: IPSC underperforms 82.33% of its industry peers.
A Quick Ratio of 1.50 indicates that IPSC should not have too much problems paying its short term obligations.
IPSC's Quick ratio of 1.50 is on the low side compared to the rest of the industry. IPSC is outperformed by 81.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.5
IPSC Yearly Current Assets VS Current LiabilitesIPSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

2

3. Growth

3.1 Past

IPSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.82%, which is quite impressive.
IPSC shows a strong growth in Revenue. In the last year, the Revenue has grown by 194.46%.
EPS 1Y (TTM)28.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.85%
Revenue 1Y (TTM)194.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1457.09%

3.2 Future

The Earnings Per Share is expected to grow by 15.51% on average over the next years. This is quite good.
Based on estimates for the next years, IPSC will show a very negative growth in Revenue. The Revenue will decrease by -25.86% on average per year.
EPS Next Y34.09%
EPS Next 2Y8.18%
EPS Next 3Y8.05%
EPS Next 5Y15.51%
Revenue Next Year1700.88%
Revenue Next 2Y53.34%
Revenue Next 3Y30.68%
Revenue Next 5Y-25.86%

3.3 Evolution

IPSC Yearly Revenue VS EstimatesIPSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
IPSC Yearly EPS VS EstimatesIPSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPSC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPSC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPSC Price Earnings VS Forward Price EarningsIPSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPSC Per share dataIPSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.18%
EPS Next 3Y8.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPSC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTURY THERAPEUTICS INC

NASDAQ:IPSC (5/2/2025, 3:36:45 PM)

0.5556

+0 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners57.69%
Inst Owner Change0.03%
Ins Owners2.55%
Ins Owner Change1.65%
Market Cap47.81M
Analysts83.33
Price Target4.9 (781.93%)
Short Float %5.76%
Short Ratio6.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.57%
Min EPS beat(2)0.1%
Max EPS beat(2)19.03%
EPS beat(4)4
Avg EPS beat(4)12.63%
Min EPS beat(4)0.1%
Max EPS beat(4)19.26%
EPS beat(8)5
Avg EPS beat(8)3.77%
EPS beat(12)7
Avg EPS beat(12)0.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)137.24%
Min Revenue beat(2)-61.68%
Max Revenue beat(2)336.16%
Revenue beat(4)1
Avg Revenue beat(4)45.01%
Min Revenue beat(4)-61.68%
Max Revenue beat(4)336.16%
Revenue beat(8)2
Avg Revenue beat(8)-6.99%
Revenue beat(12)4
Avg Revenue beat(12)-6.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-46.67%
PT rev (3m)-50.34%
EPS NQ rev (1m)13.8%
EPS NQ rev (3m)112.56%
EPS NY rev (1m)-25.4%
EPS NY rev (3m)20.4%
Revenue NQ rev (1m)19.52%
Revenue NQ rev (3m)1738.52%
Revenue NY rev (1m)1655.63%
Revenue NY rev (3m)531.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.25
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.28
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0.08
BVpS1.88
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.83%
ROE -78.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.55%
ROA(5y)-34.54%
ROE(3y)-65.22%
ROE(5y)-58.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.16%
Cap/Sales 2.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.5
Quick Ratio 1.5
Altman-Z -3.96
F-Score5
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)156.34%
Cap/Depr(5y)541.5%
Cap/Sales(3y)401.8%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.85%
EPS Next Y34.09%
EPS Next 2Y8.18%
EPS Next 3Y8.05%
EPS Next 5Y15.51%
Revenue 1Y (TTM)194.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1457.09%
Revenue Next Year1700.88%
Revenue Next 2Y53.34%
Revenue Next 3Y30.68%
Revenue Next 5Y-25.86%
EBIT growth 1Y-6.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.66%
OCF growth 3YN/A
OCF growth 5YN/A